Ensysce Biosciences (ENSC) News Today $8.00 +0.23 (+2.96%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ensysce Biosciences Inc.: Ensysce Biosciences Issues Annual Shareholder LetterJanuary 8, 2025 | finanznachrichten.deAnson Funds Management LP Buys New Stake in Ensysce Biosciences, Inc. (NASDAQ:ENSC)Anson Funds Management LP bought a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 983,518 shares of the company's stock, valued at approximately $236,000. AnsonDecember 8, 2024 | marketbeat.comEnsysce Biosciences Inc.: Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR TrialNovember 26, 2024 | finanznachrichten.deEnsysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR TrialNovember 26, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deENSC Improves PositionNovember 13, 2024 | msn.comEnsysce Biosciences Reports Improved Financial ResultsNovember 13, 2024 | markets.businessinsider.comEnsysce Biosciences receives extension to demonstrate Nasdaq complianceNovember 8, 2024 | markets.businessinsider.comEnsysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics SummitOctober 8, 2024 | finance.yahoo.comWhy Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketSeptember 30, 2024 | benzinga.comEnsysce Biosciences, Inc.: Ensysce Biosciences Submits Phase 3 Protocol to the FDASeptember 19, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces IRB Approval for Key MPAR StudyAugust 27, 2024 | finanznachrichten.deBiotech Steals The Show Following $14 Million Grant AnnouncementAugust 27, 2024 | theglobeandmail.comEnsysce Biosciences, Inc.: Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose ProtectionAugust 27, 2024 | finanznachrichten.deENSC Treatment Gets Substantial GrantAugust 27, 2024 | msn.comDiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)August 23, 2024 | globenewswire.comEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deENSC Furthers Important Drug ResearchAugust 15, 2024 | msn.comEnsysce Biosciences, Inc.: Ensysce Biosciences Provides Key Themes Following IASP 2024 SymposiumAugust 8, 2024 | finanznachrichten.deEnsysce Biosciences, Inc. (NASDAQ:ENSC): Are Analysts Optimistic?August 3, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Provides Mid-Year 2024 UpdateJuly 24, 2024 | finanznachrichten.deENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024June 24, 2024 | investorplace.comSector Update: Health Care Stocks Softer Late AfternoonMay 20, 2024 | finance.yahoo.comEnsysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 14, 2024 | finance.yahoo.comENSC: Quarterly Report Highlights ProgressMay 13, 2024 | msn.comEnsysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finanznachrichten.deEnsysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 9, 2024 | finanznachrichten.deENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023March 18, 2024 | investorplace.comENSC Striding Toward Opioid ReplacementMarch 15, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | finanznachrichten.deEnsysce Biosciences Stock (NASDAQ:ENSC), Short Interest ReportFebruary 21, 2024 | benzinga.comEnsysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose ProtectionFebruary 21, 2024 | finance.yahoo.comENSC: Investors Should Pay AttentionFebruary 16, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 15, 2024 | finanznachrichten.deEnsysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 15, 2024 | finance.yahoo.comEnsysce Biosciences falls on exercise of warrants for $4.7M gross proceedsFebruary 13, 2024 | msn.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross ProceedsFebruary 13, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceFebruary 6, 2024 | finanznachrichten.deEnsysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceFebruary 6, 2024 | finance.yahoo.comEnsysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe PainJanuary 31, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 25, 2024 | finanznachrichten.deEnsysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 25, 2024 | finance.yahoo.comEnsysce rallies 22% on FDA update for overdose-resistant opioidJanuary 23, 2024 | seekingalpha.comOpioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's WhyJanuary 23, 2024 | finance.yahoo.comENSC Announces Major FDA DesignationJanuary 23, 2024 | finance.yahoo.comEnsysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 23, 2024 | finanznachrichten.deEnsysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 23, 2024 | finance.yahoo.comEnsysce Biosciences files to sell common stock, warrantsJanuary 17, 2024 | msn.comEnsysce Biosciences, Inc.: Ensysce Biosciences Issues 2024 Shareholder LetterJanuary 8, 2024 | finanznachrichten.de Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address ENSC Media Mentions By Week ENSC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENSC News Sentiment▼0.000.60▲Average Medical News Sentiment ENSC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENSC Articles This Week▼00▲ENSC Articles Average Week Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEXX News OCX News OKYO News OMGA News SLGL News RNXT News PMN News AKTX News IXHL News LSTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENSC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
